Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039572 · ClinicalTrials.gov registry record · Phase 1
Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00039572: Completed Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
NCT00039572 is a Phase 1 study that has completed, run by Beth Israel Deaconess Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039572, a Phase 1 study, has completed, sponsored by Beth Israel Deaconess Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who have glioblastoma multiforme or melanoma metastatic to the brain.
Interventions
- DRUG boronophenylalanine-fructose complex
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-05 |
| Est. Completion | 2005-01 |
| Phase | Phase 1 |
What the finished NCT00039572 record still lists
NCT00039572 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which boronophenylalanine-fructose complex is the first listed.
NCT00039572 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00039572 about?
NCT00039572 is a clinical study titled "Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the Brain". RATIONALE: Radiation therapy such as boron neutron capture therapy may kill tumor cells without harming normal tissue. PURPOSE: Phase I/II trial to study the effectiveness of boron neutron capture therapy in treating patients who have glioblastoma multiforme or melanoma metastatic to the brain.
What is the current status of trial NCT00039572?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-05. Estimated completion is 2005-01.
What interventions are being tested in trial NCT00039572?
The interventions under investigation include: boronophenylalanine-fructose complex (DRUG).
Who is sponsoring clinical trial NCT00039572?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia